These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 28720170)

  • 1. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
    Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
    Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEVELOPMENT OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA.
    Scintee SG; Ciutan M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):371-375. PubMed ID: 28436346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AOTMiT reimbursement recommendations compared to other HTA agencies.
    Mela A; Lis D; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Drop B; Blicharski T; Niewada M
    Eur J Health Econ; 2024 Nov; 25(8):1291-1310. PubMed ID: 38261131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
    Vostalová L; Mazelová J; Samek J; Vocelka M
    Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Policy in Poland.
    Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
    Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.
    Kolasa K; Schubert S; Manca A; Hermanowski T
    Health Policy; 2011 Oct; 102(2-3):145-51. PubMed ID: 21641074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
    Malinowski KP; Kawalec P; Trąbka W
    Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN HEALTHCARE SYSTEM IN SLOVENIA.
    Prevolnik Rupel V
    Int J Technol Assess Health Care; 2017 Jan; 33(3):360-364. PubMed ID: 28434423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
    Kawalec P; Malinowski KP; Trąbka W
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
    Kawalec P; Malinowski KP
    Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From idealistic rookies to a regional leader: the history of health technology assessment in Poland.
    Nizankowski R; Wilk N
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():156-62. PubMed ID: 19527537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.